Chen, Ching-TsoChing-TsoChenFeng, Yin-HsunYin-HsunFengYen, Chia-JuiChia-JuiYenChen, San-ChiSan-ChiChenHsu, Chih-HungChih-HungHsuYU-YUN SHAO2026-01-302026-01-302025-11-07https://scholars.lib.ntu.edu.tw/handle/123456789/735674Immunotherapy combinations, such as atezolizumab plus bevacizumab (Atezo-Bev) or durvalumab plus tremelimumab, have been established as standard treatments for patients with advanced hepatocellular carcinoma (HCC). Durable responses and long-term survival have been reported following dual immunotherapy. However, the long-term outcomes associated with Atezo-Bev treatment remain unclear.To evaluate survival outcomes, we retrospectively analyzed medical records for patients with Child-Pugh class A liver function who received first-line Atezo-Bev for advanced HCC from January 2018 to May 2021 from four medical centers in Taiwan.A total of 54 patients were included in the analysis. This cohort was predominantly male (90.7%) and had a median age of 65 years. After a median follow-up period of 61.9 months, the median overall survival (OS) was 19.6 months (95% confidence interval, 10.1-20.1 months). The OS rates at 36, 48, and 60 months were 31.6%, 19.6%, and 19.6%, respectively. Younger age (≤70 years), absence of intrahepatic tumors, absence of macrovascular invasion (MVI), and Albumin-Bilirubin (ALBI) grade 1 liver function were associated with long-term survival (>36 months). A multivariate analysis revealed the absence of intrahepatic tumors (odds ratio [OR] = 5.36, p = 0.047) and ALBI grade 1 (OR = 10.02, p = 0.037) as independent predictors of long-term survival. Among patients achieving complete or partial response, the 60-month OS rate was 47.4%.Among patients with advanced HCC treated with first-line Atezo-Bev, approximately 30% survived beyond 3 years. The absence of intrahepatic tumors and preserved liver function were predictive of such prolonged survival.enImmune checkpoint inhibitorsLiver cancerLong-term survivalPrognosisjournal article10.1016/j.jfma.2025.11.00641206274